Latest filing published 16 Sept 2025 for LB PHARMACEUTICALS INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Ran Nussbaum is a declared insider at 4 companies (board member); the most frequent names are UroGen Pharma Ltd., Keros Therapeutics, Inc. and Eloxx Pharmaceuticals, Inc. Between 25 March 2021 and 12 September 2025, the trades on record add up to 11 filings.
On the market, this insider has only ever bought: 1 purchase, €1.4M in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 2 share grants and 7 option exercises.
On 16 September 2025 came the latest disclosure, a transaction in LB Pharmaceuticals Inc. The last purchase on record was published on 17 May 2021, which is 1,980 days ago. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations